CA-NEXON
12.5.2022 20:49:12 CEST | Business Wire | Press release
Today, leading game publisher Nexon announced free-to-play mobile RPG KonoSuba: Fantastic Days will be teaming up with the popular light novel and manga series, DanMachi , for a limited time crossover event from May 26 to June 9. The anime worlds of KonoSuba: Fantastic Days and DanMachi collide in an all new fantastical encounter!
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220512006001/en/
In DanMachi , a naive adventurer from the city of Orario named Bell Cranel embarks on a perilous quest in the dungeon-like catacombs underneath the city to fight monsters and a mysterious power. Along the way, Bell meets Hestia, a lonely goddess, and Ais Wallenstein, a powerful swordswoman, plus other new friends who act as his guide through the dangerous Dungeon. The KonoSuba: Fantastic Days X DanMachi collaboration treats Konofans to the unique characters and storylines from the worlds of Axel and Orario.
Konofans can pre-register starting May 12 - 25 here . Once registered, players will be able to earn special rewards through participating in the following events held on the page:
- Pre-register for Adventure!: The higher the number of cumulative pre-registers, the richer the rewards will be for all players! Players will be eligible to receive these rewards for each milestone achieved in-game from May 12 - 25.
- Countdown Bonus : Claim additional 300 Quartz daily as a countdown bonus from May 21 - 25.
- Login Bonuses : From May 26 to June 9, claim special collaboration event login bonuses every day, including two 4★ Guaranteed Recruit Tickets, a free 10x Recruit Ticket, and many other reward items during the two week period!
The KonoSuba: Fantastic Days X DanMachi events include:
- Goddess Rivalry: DanMachi’s goddess, Hestia, faces off against Konosuba’s Aqua in a new quest and story!
- Panel Missions : A new feature exclusive to this collaboration event will be introduced that rewards various items and new stones upon clearing missions.
- New Universal Missions awaits players whose shared goal and progress depend on the number of defeats of new boss, Minotaur.
- A challenging new Dungeon beckons fearless adventurers!
KonoSuba: Fantastic Days is published by Nexon in partnership with KonoSuba publisher Kadokawa, and developed by Sumzap. ©2019 N・K／K／KMP ©Sumzap, Inc. ©NEXON All Rights Reserved. ©FO-SBCr/D4
To stay up-to-date on KonoSuba: Fantastic Days , visit the Google Play or App Store page, and be sure to follow @PlayKonoSuba on Instagram and Twitter for the latest news!
Assets : Press Assets
Social Media: Twitch / Twitter / Instagram / Discord / Facebook
About DanMachi
Is It Wrong to Try to Pick Up Girls in a Dungeon? (also known as DanMachi for short) is based on Fujino Omori’s light novel of the same name which sold more than 12 million copies in total. The story follows the fresh faced Bell Cranel and his growth as he adventures through a giant city called Orario and explores the massive labyrinth “Dungeon” nestled underneath the city.
About KonoSuba: Fantastic Days konosuba.nexon.com
Based on the popular anime series “KonoSuba: God's Blessing on this Wonderful World! ”, KonoSuba: Fantastic Days is a free-to-play character-collection RPG for iOS and Android. Featuring fan-favorite characters, including Kazuma Satou, Aqua, Megumin and Darkness, the game follows the storyline from the original novel and includes bespoke characters created exclusively for the game. Last year, the Japanese release of KonoSuba: Fantastic Days saw great success, garnering recognition from players and praise from the KonoSuba fan base.
About Nexon America Inc. https://www.nexon.com/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220512006001/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Askey and Canoga Perkins Announce Strategic Collaboration at MWC Barcelona to Deliver Rapid-Deploy 5G Critical Communications Solutions27.3.2026 12:00:00 CET | Press release
Askeyand Canoga Perkinsannounced at Mobile World Congress Barcelona a Global Partnership to Deliver SyncMetra® Network Connectivity Solution, combining Canoga Perkins’ software-defined, IT-operated private 5G network transport along with Askey’s carrier-grade 5G radio access technology. At MWC Barcelona 2026, Askey Computer Corporation and Canoga Perkins announced a strategic partnership to deploy Canoga Perkins' SyncMetra® Platform across enterprise and service provider markets with Askey. This partnership pairs Askey’s carrier-grade radio access capabilities with Canoga Perkins’ industry-leading time-sensitive networking (TSN) and synchronization technology, enabling customers to simplify deployment of ultra-low-latency, highly reliable network services for 5G, edge compute, industrial automation, and mission-critical enterprise applications. The partnership enables joint go-to-market efforts, integrated product offerings, and expanded access to SyncMetra through Askey’s sales channe
SBC Medical Announces Fourth Quarter and Full Year 2025 Financial Results27.3.2026 11:40:00 CET | Press release
Q4 EPS more than doubles to $0.14 as profitability improves significantly year over year SBC Medical Group Holdings Incorporated (Nasdaq: SBC) (“SBC Medical” or the “Company”), a Management Services Organization operating a wide range of franchise businesses across diverse medical fields, today announced its financial results for the fourth quarter of fiscal year 2025 (three months ended December 31, 2025) and for the full fiscal year 2025 (twelve months ended December 31, 2025). Fourth Quarter 2025 Highlights Total revenues were $40 million, representing an 11% year-over-year decrease. Net Income attributable to SBC Medical Group was $14 million, representing a 117% year-over-year increase. Earnings per share, which is defined as net income attributable to the Company divided by the weighted average number of outstanding shares, was $0.14 for the three months ended December 31, 2025, representing 133% year-over-year increase. EBITDA1, which is calculated by adding depreciation and amo
NIQ Redefines Packaging Intelligence with Monthly, Harmonized Global Performance Visibility27.3.2026 11:00:00 CET | Press release
NIQ’s new solution brings unprecedented clarity into package types, materials, and true consumption across markets, closing critical industry gaps NielsenIQ (NYSE: NIQ), a global leader in consumer intelligence, today announced the launch of its Packaging Strategic Planner Global (SPG) Solution, the first harmonized global platform to deliver monthly visibility into packaging performance across materials, formats, and pack configurations. As packaging innovation accelerates, many organizations continue to rely on fragmented or annual data to inform packaging decisions. The Packaging SPG Solution closes this gap by providing real-time data delivered monthly across regions, enabling brands and packaging partners to uncover trends, grow revenue, and strengthen relationships with CPG and retail partners. Key Highlights: New monthly global packaging tracking capability Coverage across 200+ categories Visibility into 30+ package types and 20 package materials 10+ markets at launch, expanding
European DataWarehouse Claims Its First “Fintech Provider of the Year” Award and a Sixth “Data Provider of the Year” Title at GlobalCapital’s 2026 European Securitisation Awards27.3.2026 08:47:00 CET | Press release
European DataWarehouse (EDW) is pleased to announce that it has been named both “Data Provider of the Year” and “Fintech Provider of the Year” at the 2026 GlobalCapital European Securitization Awards in London. The award ceremony recognises outstanding achievements in European structured finance, with winners selected by popular vote from across the industry. As defined by GlobalCapital, the programme celebrates “the very best in the market, as chosen by the market.” This latest recognition marks the sixth time that EDW has received the prestigious Data Provider of the Year award, having previously been honoured in 2019, 2022, 2023, 2024 and 2025, reaffirming its long-standing commitment to transparency, data quality and innovation in European securitisation. Prof. José Manuel González-Páramo, Chairman of EDW, later commented: “ Winning this award for the sixth time highlights the continued trust the European securitisation market places in EDW. Transparency, data quality and reliabili
Biocytogen Announces FDA IND Clearance for Partner NEOK Bio’s NEOK002 Targeting Solid Tumors27.3.2026 01:00:00 CET | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that its partner NEOK Bio, Inc. recently received clearance from the U.S. Food and Drug Administration (FDA) of an investigational new drug (IND) application for NEOK002, an EGFR/MUC1-targeting ADC program for solid tumors. NEOK Bio plans to initiate a Phase 1 clinical study in the second quarter of 2026 and expects to report initial data in 2027. This IND clearance marks an important milestone for NEOK002, an EGFR/MUC1-targeting ADC candidate developed by NEOK Bio and built on a bispecific antibody originally developed by Biocytogen and licensed in 2024. According to NEOK Bio, NEOK002 is being advanced for solid tumors and may offer differentiated efficacy and safety compared with monospecific ADC approaches directed at either target alone. Dr. Yuelei Sh
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom